AM-Pharma

Meet our CEO, Juliane Bernholz, PhD, at the American Society of Nephrology Kidney Week 2024 in San Diego, from October 23-27. #KidneyWeek is the world's premier nephrology meeting and a platform to discuss the latest scientific and medical advances in kidney disease. On Thursday, October 24, at 4:30 pm PT, Prof. Peter Pickkers will be presenting in the session: “Emerging Therapies for AKI: Bright Horizons”, to discuss ilofotase alfa and the reno-protective effects observed in REVIVAL and our ongoing Phase 2 study in cardiac surgery-associated renal damage, a severe surgical complication that can lead to long-term impairment of kidney function. #nephrology #renaldamage

On #WorldHeartDay, we say “YES” to inspire action for heart health and raise awareness of heart conditions like cardiac-surgery-associated renal damage (CSA-RD), a critical surgical complication for which there is no pharmacological therapy. CSA-RD arises from acute kidney injury following open-heart surgery and can result in the need for renal replacement therapy such as dialysis. We are currently evaluating ilofotase alfa as a preventative treatment for CSA-RD in a Phase 2 clinical trial. Together with the World Heart Federation, we invite you to sign the petition for national heart action plans around the world: https://lnkd.in/gzNcyzwb. #UseHeart #WorldHeartDay #HeartYes #CSARD

Make sure to attend the presentations on September 26 at 3:45 pm ET and September 29 at 4:30 pm ET, by Dr. Lothar Seefried, University of Wuerzburg, on the results of our open-label Phase 1b study evaluating ilofotase alfa in adult hypophosphatasia (HPP) patients. At the American Society for Bone and Mineral Research (ASBMR) Annual Meeting in Toronto, Canada, held from September 27-30, Dr. Lothar Seefried will discuss the pronounced effect on all HPP disease-relevant biomarkers together with a positive safety and tolerability profile that ilofotase alfa achieved in adult HPP patients. Our CEO, Juliane Bernholz, PhD, is also attending the conference and is looking forward to discussing AM-Pharma’s development plan for ilofotase alfa as a new treatment for hypophosphatasia. #hypophosphatasia #HPP #ASBMR

Check out Scrip’s report on the roundtable discussion, “Preparing for First-in-Human: Overcoming Obstacles & Seizing Opportunities in Early Phase Biotech Research” that our CEO, Juliane Bernholz, PhD attended as a panelist during the Swiss Biotech Days. https://lnkd.in/exgCb6dZ #BiotechResearch #ScienceRoundtable 

Join us for engaging discussions at the Critical Care Clinical Trialists Workshop in Washington, DC, from June 13-15. Peter Pickkers, MD, PhD, Principal Investigator, will present the trial design for our ongoing Phase 2 study assessing ilofotase alfa as a preventative treatment for cardiac surgery-associated renal damage. Don’t miss his oral presentation on Thursday, June 13 during Session 2 from 10:50 am – 12 pm EDT.                                                                                                          Our Senior Director, Project Management Office, Liesbeth Hof will provide her industry perspectives to Session 5, “Positive trials in critical care: the key role of regulators” from 5:00 pm – 6:45 pm EDT on Thursday, June 13. #3ct #criticalcare #clinicalresearch

The 42nd Vicenza Critical Care Nephrology Course is taking place from June 11-13 and our CEO, Juliane Bernholz, PhD will be attending on-site.   Additionally, Peter Pickkers, MD, PhD, Principal Investigator of the Phase 3 REVIVAL study, participated in a virtual “Cappuccino with Claudio” series in which he discussed a new approach for addressing cardiac surgery-related renal damage with ilofotase alfa with Claudio Ronco, MD, Director of the International Renal Research Institute of Vicenza. Watch the full interview with Professor Ronco and Professor Pickkers for an engaging conversation about the Phase 3 REVIVAL results, the potential reno-protective effect of ilofotase alfa, and how we have built on these data to design and conduct our ongoing Phase 2 cardiac surgery-associated renal damage study. →https://lnkd.in/eTsR6yQX #42VicenzaCourse #CriticalCare #ClinicalResearch #Nephrology

Meet our CEO, Juliane Bernholz, PhD, at the BIO International Convention in San Diego from June 3-6. Book a one-on-one meeting with Juliane to learn about AM-Pharma’s recent corporate and clinical milestones and upcoming development plans to provide new treatments for patients living with severe medical conditions, notably hypophosphatasia (HPP) and Acute Kidney Injury (AKI). #BIO2024 #hypophosphatasia #AKI

Our CEO, Juliane Bernholz, PhD, will be holding a corporate presentation at Bio€quity Europe 2024, held in San Sebastián, Spain, from May 12-14. Join her talk on Tuesday, May 14 at 10:00 am CEST in Room 9 or book a one-on-one meeting to discuss AM-Pharma’s recent progress in developing ilofotase alfa for the treatment of severe medical conditions, particularly hypophosphatasia (HPP) and Acute Kidney Injury (AKI). #BioEquityEurope #hypophosphatasia #AKI

During the Swiss Biotech Days, our CEO, Juliane Bernholz, PhD, participated in a roundtable discussion hosted by Scrip on the topic of “Preparing for First-in-Human: Overcoming Obstacles & Seizing Opportunities in Early Phase Biotech Research.” Dr. Bernholz and fellow key opinion leaders provided insights into the important steps to follow when taking an asset from preclinical studies to first-in-human trials. Stay tuned for the upcoming article by Scrip on the discussion.

Our CEO, Juliane Bernholz, PhD, will attend the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases in London from April 11-14. The 24th Edition of the WCO-IOF-ESCEO will bring together experts from around the world to discuss the latest research and therapeutic strategies for musculoskeletal diseases, including hypophosphatasia (HPP), a rare disorder characterized by bone injuries and extreme muscle pain and weakness. Meet with Dr. Bernholz to learn about our recent clinical progress in developing ilofotase alfa for the treatment of HPP. #WCOIOFESCEO #HPP